HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NXL
Nexalin Technology, Inc.
NXL lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NXL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
NXL's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NXL PE Valuation
NXL has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NXL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect NXL's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NXL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.63 | +$6.47 |
| Q2 2026 | -$14.10 | +$9.00 |
| Q1 2026 | -$13.80 | +$11.40 |
| Q4 2025 | -$15.00 | +$9.90 |
| Q3 2025 | -$20.10 | -$0.68 |
| Q2 2025 | -$23.10 | -$1.28 |
| Q1 2025 | -$25.20 | -$5.18 |
| Q4 2024 | -$24.90 | -$6.00 |
NXL is still losing money, but far less than before: $13.63 per share over the past year, against $34.20 at its worst in late 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NXL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NXL on profitability, with a higher operating margin.
NXL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $78.3K | +331% |
| Q2 2026 | $12.2K | -83% |
| Q1 2026 | $15K | -64% |
| Q4 2025 | $171.9K | +532% |
| Q3 2025 | $18.1K | -50% |
| Q2 2025 | $70.6K | +163% |
| Q1 2025 | $41K | -48% |
| Q4 2024 | $27.2K | +32% |
NXL's revenue is recovering but still below its 2022 peak: $78,301 last quarter, up 331% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3332% | +9592 points |
| Q2 2026 | -18480% | -16184 points |
| Q1 2026 | -14180% | -9276 points |
| Q4 2025 | -1404% | +9176 points |
| Q3 2025 | -12924% | -5962 points |
| Q2 2025 | -2296% | +2536 points |
| Q1 2025 | -4904% | -3539 points |
| Q4 2024 | -10579% | -2669 points |
NXL's operating margin was −3332% last quarter, up 9592 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NXL on cash generation, producing positive trailing cash flow while its opponent burns cash.
NXL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6M | -$121.5K |
| Q2 2026 | -$1.8M | -$884.5K |
| Q1 2026 | -$1.7M | -$286.8K |
| Q4 2025 | -$1.1M | -$13.5K |
| Q3 2025 | -$1.5M | -$666K |
| Q2 2025 | -$917.2K | +$329.3K |
| Q1 2025 | -$1.4M | -$662.9K |
| Q4 2024 | -$1.1M | -$130.4K |
NXL has burned cash in almost every quarter: −$6M over the past year, against −$5M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NXL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NXL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +71.9K shares |
| 1 year | +48% | +253K shares |
| 3 years | +220% | +534K shares |
| 5 years | +376% | +613K shares |
NXL has 776,657 diluted shares, up 48% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NXL Net Leverage
NXL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NXL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.1 | Oversold |
| Stochastic | 1.3 | Oversold |
NXL's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NXL PE vs Healthcare Sector
NXL has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NXL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.81 | 47% below |
| 20 week MA | $6.97 | 79% below |
| 50 week MA | $12.1 | 88% below |
| 100 week MA | $31.0 | 95% below |
| 200 week MA | $31.2 | 95% below |
NXL is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NXL on returns for 2026, with the stronger performance.
NXL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $67.5 | $23.4 | -65% |
| 2023 | $23.4 | $12.1 | -48% |
| 2024 | $12.1 | $88.5 | +629% |
| 2025 | $88.5 | $18.9 | -79% |
| 2026 YTD | $18.9 | $1.49 | -92% |
NXL's yearly returns have swung widely, from +629% in 2024 to −79% in 2025. It's down 92% so far in 2026.